Participants were sequentially enrolled and randomized within dose escalating cohorts to receive three vaccinations on days 0 , 28 and 56 of either 20 microg of AMA1-C1 / Alhydrogel +564 microg CPG 7909 ( n = 15 ) , 80 microg of AMA1-C1 / Alhydrogel ( n = 30 ) , or 80 microg of AMA1-C1 / Alhydrogel +564 microg CPG 7909 ( n = 30 ) .
